Drug Profile
SCR 1515
Alternative Names: SCR-1515Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Cancer in China (unspecified route)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Cancer in China
- 14 Aug 2015 Preclinical trials in Cancer in China (unspecified route)